AbbVie is one of America's most prominent biopharmaceutical companies, spun out of Abbott Laboratories in 2013 and built around a commercial drug portfolio of considerable scale and reach. Listed on the NYSE under the ticker ABBV, the company is perhaps best known as the maker of Humira, for many years the world's best-selling prescription medicine, though its strategic priority in recent years has been diversifying beyond Humira as biosimilar competition has eroded that franchise.
The diversification effort has been substantial. AbbVie's acquisitions of Allergan and a series of oncology and immunology assets have broadened the pipeline meaningfully, with Skyrizi and Rinvoq emerging as the next generation of growth drivers. For traders, AbbVie is an interesting combination of defensive pharmaceutical income: the company has a strong dividend track record and binary event risk around clinical trial outcomes and regulatory decisions that can move the share price sharply in either direction.
Please note this is marketing communication, not recommendation or advice.
cuentas de clientes
FxPro brinda servicios comerciales en línea a clientes desde 1999 y actualmente brinda servicios a 173 países en todo el mundo.
Premios
FxPro ha recibido un reconocimiento constante en la industria, ganando más de 145 premios internacionales hasta la fecha por la calidad de sus servicios.
Servicio al Cliente
Nuestro dedicado equipo de servicio al cliente multilingüe trabaja las 24 horas del día, los 5 días de la semana para brindarle un nivel excepcional de soporte.
regulaciones de la industria
FxPro opera bajo estricta supervisión regulatoria en múltiples jurisdicciones, incluida la autorización de la FCA en el Reino Unido, uno de los reguladores financieros más confiables a nivel mundial.
